Skip to main
MPLT

MPLT Stock Forecast & Price Target

MPLT Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MapLight Therapeutics Inc. is positioned favorably in the biopharmaceutical sector with its promising product candidate ML-007C-MA, which has shown potential to be a best-in-class M1/M4 agonist, indicating a solid differentiator in the competitive landscape. Phase 1 and preclinical data highlight ML-007C-MA's improved tolerability and dosing convenience compared to existing treatments, alongside statistically significant improvements in sociability and aggression in preclinical models. The favorable outcomes from the ZEPHYR trial further suggest the likelihood of substantial market uptake, reinforcing a positive outlook on the company’s future performance and product pipeline.

Bears say

MapLight Therapeutics Inc faces significant challenges in the competitive schizophrenia market, entering years behind other candidates like KarXT and contending with a low bar for success despite prior blockbuster sales of minimally differentiated antipsychotics. The company’s Phase 3 readout expectations are tempered by clinical trial delays and a higher-risk profile, which heightens skepticism regarding its pipeline's viability. Furthermore, MapLight's current market cap of approximately $800 million, reflecting less than 1x the unadjusted peak sales potential for schizophrenia treatments, raises concerns about its valuation, particularly under adverse scenarios that drastically decrease projected approval probabilities.

MPLT has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MapLight Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MapLight Therapeutics Inc (MPLT) Forecast

Analysts have given MPLT a Strong Buy based on their latest research and market trends.

According to 5 analysts, MPLT has a Strong Buy consensus rating as of Mar 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MapLight Therapeutics Inc (MPLT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.